Clinical trial
rhEndostatin Protein Involving Pediatric Patients With Cancer
NCT00165373 · Dana-Farber Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00165373 |
|---|---|
| Title | rhEndostatin Protein Involving Pediatric Patients With Cancer |
| Official title | A Phase I, Safety, Pharmacokinetic and Pharmacodynamic Study of rhEndostatin Protein Administered by Continuous Intravenous Infusion to Pediatric Patients With Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Boston Children's Hospital |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors |
| Intervention type | Drug |
| Interventions | rhEndostatin |
| Enrollment | 21 |
| Start date | Jan 1, 2003 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Dec 28, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: